Core Viewpoint - The innovative drug sector experienced a significant drop in both Hong Kong and A-share markets, with declines exceeding 6% in various segments, including oncology and CXO [1][3]. However, research institutions view this downturn as a buying opportunity, suggesting that the upward trend in the pharmaceutical sector is likely to continue in the medium to long term [1][6]. Market Performance - Early trading saw a collective decline in the innovative drug sector, with notable stocks like BeiGene and Eucure Biopharma dropping over 10% [1]. The decline was later mitigated, with Eucure Biopharma turning positive and BeiGene's drop narrowing to under 5% [2]. External Factors - A sudden market downturn was attributed to concerns over potential U.S. government restrictions on drug imports from China, which could disrupt experimental therapies and impact the U.S. pharmaceutical industry [4]. However, the White House indicated that there was no active consideration of such a proposal [5]. Analyst Insights - Despite the negative news, analysts from Dongwu Securities and Guotai Junan believe that the downturn presents a buying opportunity, emphasizing the competitive advantage of Chinese innovative drug companies in the U.S. biotech landscape [6][7]. They argue that the profitability of multinational corporations (MNCs) from Chinese drug pipelines remains significant, with MNCs benefiting more from the profits generated [6]. Long-term Outlook - Analysts from Citic Securities maintain that the pharmaceutical sector's upward momentum is far from over, recommending a focus on innovation-driven and internationalization strategies, particularly in sectors with strong domestic demand [7]. The potential impact of any administrative orders is considered limited, given the historical challenges faced by similar policies in the U.S. judicial system [7].

Group 1 - The innovative drug concept stocks opened lower on September 11, with companies like BeiGene and Tigermed experiencing declines of over 10% [1] - WuXi AppTec fell by more than 7%, while other companies such as HengRui Medicine, Yuandong Bio, Huahai Pharmaceutical, and Saili Medical saw declines exceeding 5% [1] - After half an hour of trading, BeiGene's decline narrowed to below 7%, resulting in a market value loss of over 30 billion yuan compared to the previous trading day [1]

9月11日早盘，创新药概念股低开，百济神州、泰格医药一度跌超10%，盘中最低价278.9元/股；药明康 德跌超7%，恒瑞医药，苑东生物、华海药业、塞力医疗等多股跌超5%。开盘半小时后，百济神州跌幅 缩窄至7%以下，较前一交易日，其A股最新市值蒸发超300亿。 （文章来源：第一财经） ...

Group 1 - The overall performance of the pharmaceutical industry is weak, with an average revenue growth of 1.6% and a decline in average net profit by 3.2% for the first half of 2025 compared to the full year of 2024 [2] - The industry is expected to take time for performance improvement, with ongoing support policies for innovative drugs and devices, as well as improvements in global biopharmaceutical financing driving recovery [2] - A significant drop in stock prices was observed among innovative drug concept stocks in the Hong Kong market, with Huaneng Pharmaceutical down nearly 15% and Kelun-Bio down over 12% [4] Group 2 - The report by CMB International analyzed the performance of 393 pharmaceutical companies listed in A-shares and Hong Kong stocks, indicating a deterioration in both revenue and profit compared to the previous year [2] - The domestic centralized procurement policy optimization and continuous support for innovative drugs and devices are seen as crucial for the industry's recovery [2] - The stock performance of various pharmaceutical companies reflects the overall market sentiment, with multiple companies experiencing declines exceeding 9% [4]

Market Overview - The A-share market opened with mixed results, with the Shanghai Composite Index down by 0.16%, the Shenzhen Component Index up by 0.11%, and the ChiNext Index up by 0.46% [3][4] - The Hang Seng Index opened down by 0.81%, and the Hang Seng Tech Index fell by 0.97% [6][7] Pharmaceutical Sector Performance - The innovative drug concept stocks experienced significant declines, with BeiGene falling over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like Hengrui Medicine, Junshi Biosciences, and Kelun Pharmaceutical dropping over 5% [2][6] - The pharmaceutical sector as a whole saw a downturn, with various sub-sectors such as medical services, weight loss drugs, and CRO concepts all reporting negative performance, with declines ranging from -1.13% to -1.99% [5] Notable Stock Movements - Specific stocks such as Hansoh Pharmaceutical and WuXi Biologics dropped over 10%, while Jiangsu Hengrui Medicine and Junshi Biosciences also faced significant losses [6] - Conversely, some stocks like Jiujiuwang Pharmaceutical saw a rise of 5% despite the overall market trend [6]

| 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | MAN | 3806.06c | -6.16 | -0.16% | | 399001 | 深证成指 | W | 12570.87c | 13.19 | 0.11% | | 399006 | 创业板指 | A / | 2917.77c | 13.50 | 0.46% | 2025.09. 11 本文字数：503，阅读时长大约1分钟 作者 | 一财阿驴 09:28 创新药概念股大幅低开，百济神州跌超10%，药明康德、泰格医药跌超7%，恒瑞医药、君实 生物、凯莱英多股跌超5%。 09:26 A股开盘丨三大指数涨跌不一 上证指数跌0.16%，深成指涨0.11%，创业板指涨0.46%。盘面上，医药股大幅下挫，药明康德、泰 格医药低开逾7%；CPO、算力概念活跃。 你不是一个人在奋斗，阿驴都懂。 「 生产队的驴 」 IP原创帆布包 | | 사용이문 수 | | | --- | --- | --- | | 医疗服务 | -1.99% | +0.0 ...

09:26 A股开盘丨三大指数涨跌不一 上证指数跌0.16%，深成指涨0.11%，创业板指涨0.46%。盘面上，医药股大幅下挫，药明康德、泰格医药低开逾7%；CPO、算力概念活 跃。 | 代码 | 名称 | 两日图 | 现价 | 消費 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | MM | 3806.06c | -6.16 | -0.16% | | 399001 | 深证成指 | W | 12570.87 c | 13.19 | 0.11% | | 399006 | 创业板指 | A / | 2917.77c | 13.50 | 0.46% | 盘面上，医药股大幅下挫，药明康德、泰格医药低开逾7%；CPO、算力概念活跃。 09:28 创新药概念股大幅低开，百济神州跌超10%，药明康德、泰格医药跌超7%，恒瑞医药、君实生物、凯莱英多股跌超5%。 恒指低开0.81%，恒生科技指数跌0.97%。医药股大面积下跌，瀚森制药、药明生物跌超10%，药捷安康逆势涨5%；科网股普遍回调，蔚 来宣布再融资后跌超3%，百度集团跌逾3%；鸿腾精密续涨 ...

百济神州开盘走低，现跌超8%。 ...

每经AI快讯，9月10日，百济神州美股盘前一度跌超12%，现跌幅收窄至9%。 （文章来源：每日经济新闻） ...

每经AI快讯，9月10日，百济神州美股盘前一度跌超12%，现跌幅收窄至9%。 ...